Born in Barcelona in 1968. He holds a degree in Telecommunications Engineering from the Polytechnic University of Catalonia, Barcelona, a Master’s in Communication Networks from the École Supérieure d’Ingénieurs Télécom ParisTech, Paris, and an MBA from IESE Business School, Barcelona, and the University of California, Berkeley (USA), where he experienced the dot-com boom.
After a career in the digital media sector, in 2006 he became CEO of REIG JOFRE, the pharmaceutical company founded by his grandfather in 1929. Under his leadership, the company has grown to become the fifth-largest pharmaceutical company in Spain by revenue, publicly listed (RJF), with over 1,400 employees, four R&D and production centers in Europe, direct presence in eight countries, and distribution in over 70 countries.
Ignasi Biosca has led REIG JOFRE’s transformation into a global company with a clear purpose: making health solutions that truly matter accessible to everyone, from prevention and wellness to critical treatments. He has strengthened the company’s three business units:
- Pharmaceutical Technologies – specializing in sterile injectables, lyophilized products, and hospital-use beta-lactam antibiotics.
- Specialty Pharmacare – mainly prescription drugs in dermatology and musculoskeletal treatments.
- Consumer Healthcare – dietary supplements for prevention and wellness under the Forté Pharma brand, mainly in France, Belgium, Spain, and Portugal, as well as ENT products and topical disinfectants.
His strategy emphasizes open innovation, advanced manufacturing technology, and internationalization. A firm believer in collaboration as a driver of innovation, he has promoted strategic alliances with research centers and start-ups, including the creation of Syna Therapeutics and partnerships for advanced therapies.
Under his management, REIG JOFRE has become an industrial benchmark in the validation and scaling of new pharmaceutical technologies, with a strong commitment to sustainability, social impact, and the creation of skilled jobs in Europe.
He also serves as a member of the Governing Council and Board of Directors of Farmaindustria, Second Vice President and Board Member of Biocat, and participates on the boards of various biotech companies. He was President of CataloniaBio from 2014 to 2018.
